These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 31567148)

  • 1. Afatinib Achieved Remarkable Disease Control in a Chinese Patient With Lung Adenocarcinoma Harboring Rare EGFR Exon 18-25 Kinase Domain Duplication.
    Wang XF; Zhao QT; Chen C
    Am J Ther; 2020; 27(5):e535-e537. PubMed ID: 31567148
    [No Abstract]   [Full Text] [Related]  

  • 2. Major Clinical Response to Afatinib Monotherapy in Lung Adenocarcinoma Harboring EGFR Exon 20 Insertion Mutation.
    Urbán L; Dóczi R; Vodicska B; Tihanyi D; Horváth M; Kormos D; Takács I; Pápai-Székely Z; Póka-Farkas Z; Várkondi E; Schwáb R; Hegedüs C; Vályi-Nagy I; Peták I
    Clin Lung Cancer; 2021 Jan; 22(1):e112-e115. PubMed ID: 33082101
    [No Abstract]   [Full Text] [Related]  

  • 3. Identification of a Novel MET Exon 14 Skipping Variant Coexistent with EGFR Mutation in Lung Adenocarcinoma Sensitive to Combined Treatment with Afatinib and Crizotinib.
    Zeng L; Xia C; Zhang Y; Yang N
    J Thorac Oncol; 2019 Apr; 14(4):e70-e72. PubMed ID: 30922580
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy of afatinib treatment for lung adenocarcinoma harboring exon 18 delE709_T710insD mutation.
    Iwamoto Y; Ichihara E; Hara N; Nakasuka T; Ando C; Umeno T; Hirabae A; Maeda Y; Kiura K
    Jpn J Clin Oncol; 2019 Aug; 49(8):786-788. PubMed ID: 31187861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary Resistance to Afatinib in a Patient with Lung Adenocarcinoma Harboring Uncommon EGFR Mutations: S768I and V769L.
    Niogret J; Coudert B; Boidot R
    J Thorac Oncol; 2018 Jul; 13(7):e113. PubMed ID: 29935845
    [No Abstract]   [Full Text] [Related]  

  • 6. EGFR exon 18 DelE709_T710insD as an Acquired Resistance Mechanism to Afatinib in an Advanced EGFR exon 18 E709H Lung Adenocarcinoma.
    Zeng L; Zhang Y; Yang N
    J Thorac Oncol; 2018 Jun; 13(6):e93-e95. PubMed ID: 29793651
    [No Abstract]   [Full Text] [Related]  

  • 7. Sunvozertinib overcoming resistance to afatinib and osimertinib in lung adenocarcinoma harboring an EGFR exon 18 DelE709_T710insD mutation.
    Ding K; Peng Z; Liu D; Xu Y
    J Transl Med; 2024 Aug; 22(1):761. PubMed ID: 39143613
    [No Abstract]   [Full Text] [Related]  

  • 8. Successful Treatment of Lung Adenocarcinoma with Epidermal Growth Factor Receptor Compound Mutations Involving Exon 19 Deletion and Exon 20 Insertion by Afatinib.
    Ikeuchi T; Tokuyasu H; Ishikawa S
    Intern Med; 2019; 58(1):101-104. PubMed ID: 30606938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Hyponatremia in a 58-year-old female patient with EGFR-positive lung adenocarcinoma].
    Koch M; Utpatel K; Schulz C
    Internist (Berl); 2018 Apr; 59(4):384-387. PubMed ID: 28980030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Afatinib and Cetuximab in Four Patients With EGFR Exon 20 Insertion-Positive Advanced NSCLC.
    van Veggel B; de Langen AJ; Hashemi SMS; Monkhorst K; Heideman DAM; Thunnissen E; Smit EF
    J Thorac Oncol; 2018 Aug; 13(8):1222-1226. PubMed ID: 29702285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Afatinib is effective in the treatment of lung adenocarcinoma with uncommon EGFR p.L747P and p.L747S mutations.
    Liang SK; Ko JC; Yang JC; Shih JY
    Lung Cancer; 2019 Jul; 133():103-109. PubMed ID: 31200815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful treatment of a lung adenocarcinoma patient with a novel EGFR exon 20-ins mutation with afatinib: A case report.
    Cai Y; Wang X; Guo Y; Sun C; Xu Y; Qiu S; Ma K
    Medicine (Baltimore); 2019 Jan; 98(1):e13890. PubMed ID: 30608413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Afatinib as first-line treatment for advanced lung adenocarcinoma patients harboring HER2 mutation: A case report and review of the literature.
    Shi Y; Wang M
    Thorac Cancer; 2018 Dec; 9(12):1788-1794. PubMed ID: 30379401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term survival in a patient with advanced lung adenocarcinoma harboring synchronous EGFR exon 18 G719A and BRAF V600E mutations and treated with afatinib: a case report.
    Huang Q; Chen C; Hu S; Wu H; Yu D; Zhu X; Xue C; Wu Y; Tang J; Xie R; Ran F
    Anticancer Drugs; 2022 Jan; 33(1):e730-e733. PubMed ID: 34387589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EGFR exon 18 delE709_T710insD mutated stage IV lung adenocarcinoma with response to afatinib.
    Ibrahim U; Saqib A; Atallah JP
    Lung Cancer; 2017 Jun; 108():45-47. PubMed ID: 28625646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Afatinib response in a lung adenocarcinoma with novel compound S720F+L861R mutation in EGFR.
    Zhang X; Jiang W; Yang N; Zhang Y
    Lung Cancer; 2020 Oct; 148():170-172. PubMed ID: 32660759
    [No Abstract]   [Full Text] [Related]  

  • 17. Complex epidermal growth factor receptor mutations and their responses to tyrosine kinase inhibitors in previously untreated advanced lung adenocarcinomas.
    Zhang B; Wang S; Qian J; Yang W; Qian F; Lu J; Zhang Y; Qiao R; Han B
    Cancer; 2018 Jun; 124(11):2399-2406. PubMed ID: 29543321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Durable Response of Low-Dose Afatinib plus Cetuximab in an Adenocarcinoma Patient with a Novel EGFR Exon 20 Insertion Mutation.
    Fang W; Huang Y; Gan J; Shao YW; Zhang L
    J Thorac Oncol; 2019 Oct; 14(10):e220-e221. PubMed ID: 31558231
    [No Abstract]   [Full Text] [Related]  

  • 19. Afatinib in the Treatment of Advanced Non-Small Cell Lung Cancer with Rare EGFR (in exon 18-T179X) Mutation - a Case Report.
    Čoupková H; Vyzula R
    Klin Onkol; 2018; 31(5):380-383. PubMed ID: 30541326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib.
    Yamaoka T; Ohba M; Matsunaga Y; Tsurutani J; Ohmori T
    J Vis Exp; 2019 Jun; (148):. PubMed ID: 31305510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.